Regulus Therapeutics Inc (RGLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Regulus Therapeutics Inc (RGLS) has a cash flow conversion efficiency ratio of -0.154x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.61 Million) by net assets ($69.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Regulus Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
Regulus Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Regulus Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Regulus Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Regulus Therapeutics Inc ranked by their cash flow conversion efficiency. See how well can Regulus Therapeutics Inc service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shandong Wohua Pharmaceutical Co Ltd
SHE:002107
|
0.028x |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212
|
N/A |
|
MAS Financial Services Limited
NSE:MASFIN
|
-0.330x |
|
Shanghai GuAo Electronic Technology Co Ltd
SHE:300551
|
-0.038x |
|
Hubei Kailong Chemical Group Co Ltd
SHE:002783
|
0.000x |
|
Nantong Square Cold Chain Equipment Co Ltd
SHG:603339
|
0.049x |
|
Global PMX Co Ltd
TW:4551
|
0.052x |
|
ForFarmers NV
AS:FFARM
|
0.194x |
Annual Cash Flow Conversion Efficiency for Regulus Therapeutics Inc (2010–2024)
The table below shows the annual cash flow conversion efficiency of Regulus Therapeutics Inc from 2010 to 2024. View latest Regulus Therapeutics Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $76.41 Million | $-41.67 Million | -0.545x | +56.83% |
| 2023-12-31 | $21.19 Million | $-26.77 Million | -1.263x | -64.77% |
| 2022-12-31 | $33.29 Million | $-25.53 Million | -0.767x | -74.65% |
| 2021-12-31 | $54.96 Million | $-24.13 Million | -0.439x | +8.85% |
| 2020-12-31 | $26.03 Million | $-12.54 Million | -0.482x | +51.36% |
| 2019-12-31 | $20.02 Million | $-19.82 Million | -0.990x | -113.40% |
| 2018-12-31 | $-5.85 Million | $-43.27 Million | 7.392x | +542.92% |
| 2017-12-31 | $35.22 Million | $-58.77 Million | -1.669x | -64.53% |
| 2016-12-31 | $56.08 Million | $-56.88 Million | -1.014x | -152.44% |
| 2015-12-31 | $124.08 Million | $-49.86 Million | -0.402x | -34.26% |
| 2014-12-31 | $132.01 Million | $-39.51 Million | -0.299x | +1.27% |
| 2013-12-31 | $93.46 Million | $-28.33 Million | -0.303x | -115.83% |
| 2012-12-31 | $62.09 Million | $-8.72 Million | -0.140x | -138.69% |
| 2011-12-31 | $-41.49 Million | $-15.06 Million | 0.363x | -76.41% |
| 2010-12-31 | $8.00 Million | $12.31 Million | 1.539x | -- |
About Regulus Therapeutics Inc
Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target o… Read more